

ASX Release

Anatara Expands Executive Team

Key points:

- **CEO, Dr Paul Schober to retire and Chairman, Dr Mel Bridges to transition to Chairman & CEO role**
- **Dr Michael West appointed Chief Operating Officer (COO)**
- **Ms Kylie Davis appointed Clinical Trials Manager**

BRISBANE, 27th June 2016: Anatara Lifesciences (ASX:ANR) announces changes to its management team, including the retirement of Dr Paul Schober as CEO, transition of Dr Mel Bridges into a combined CEO / Chairman role as well as the appointment of Dr Mike West as COO and Ms Kylie Davis as Clinical Trials Manager.

The Company has accepted CEO, Dr Paul Schober's plans to move to retirement over the next three months as part of a closely managed transition plan, commencing Monday 27th June 2016.

Dr Bridges said, "We have a very close relationship with Paul, and expect this to be a smooth transition, aided strategically by a number of new appointments and a generous notice period. Paul has been critical to Anatara's early growth plans, following our 2014 ASX listing and played a key role in deploying the early strategic plan that has led the Company to the strong position that it's in today."

Anatara is also pleased to announce the appointment of Dr Michael West as Chief Operating Officer (COO), effective Friday 1st July 2016.

Dr West has extensive global GMP manufacturing, regulatory and drug launch scale-up expertise, including experience with global drug company SmithKline Beecham (now GSK) in the USA, Alchemia Limited and the Centre for Drug Design & Development at the University of Queensland. Dr West has served on the Pharmaceutical subcommittee to the Australian Drug Evaluation Committee at the Therapeutic Goods Administration (TGA).

Dr West will report directly to Dr Bridges and form part of the senior leadership team – also reporting to the board. Dr West will assume ownership for key areas of responsibility that have been managed to date by Dr Schober.

Dr Schober said, "I am very confident that Dr West will assume strategic management of my key responsibilities, and I will work closely with Michael over the next three months to ensure a seamless transition. I remain a founding shareholder of Anatara and am absolutely committed to making myself available to assist the team with executing the Company's strategic plans."



In a move to further strengthen its clinical trial capability, Anataara is pleased to announce the appointment of Ms Kylie Davis as its Clinical Trials Manager reporting to Co-Founder and CSO, Dr Tracey Mynott. Kylie was formerly a senior veterinary clinical research associate with leading global animal health company, Zoetis. She has over 9 years' experience coordinating and monitoring all aspects of veterinary clinical studies, both in Australia and internationally, including trials in pigs, cattle, poultry and in companion animals. She comes with experience in requirements for registration of veterinary products internationally.

Dr Bridges said, "The new executive team appointments will provide Dr Mynott more time to focus on moving the animal health initiatives to completion, as the Company increases its over-the-counter (OTC) opportunities in the human area."

"I am looking forward to re-assuming a leadership role in corporate communications and investor relations. I have purposefully scaled back my corporate commitments over the course of this year to give me the time to provide focussed commitment to Anataara. As the Company's largest shareholder I have a strong vested interest in ensuring we execute on our strategic goals," Dr Bridges added.

The Anataara team plans a further market update and investor roadshow in July.

For more information please contact:

Investor inquiries	Media inquiries
<p>Dr Mel Bridges Chairman, Anataara Lifesciences +61 (0) 413 051 600 melbridges@parmacorp.com</p> <p>Dr Tracey Mynott CSO, Anataara Lifesciences +61 (0) 405 050 113 tmynott@anataralifesciences.com</p>	<p>Jane Lowe IR Department +61 (0) 411 117 774 jane.lowe@irdepartment.com.au</p>

About Anataara Lifesciences

Anataara Lifesciences is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach™ is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called "super bugs" that make infectious diseases harder to treat. The Anataara team has a strong track record in biological science as well as building and growing international biotech companies.